BrainStorm Cell Stock Surges As NurOwn Aces Mid-Stage Multiple Sclerosis Study

BrainStorm Cell Therapeutics Inc BCLI has reported topline Phase 2 data evaluating three repeated administrations of NurOwn (MSC-NTF cells), each given two months apart, as a treatment for progressive multiple sclerosis (MS).

  • The study achieved the primary endpoint of safety, and improvements were observed in secondary endpoints spanning neurologic function, cognition, and biomarkers.
  • Prespecified 25% improvements in the timed 25-foot walk and 9-hole peg test from baseline to 28 weeks were observed in 14%, and 13% of NurOwn treated patients, respectively, compared to 0% in matched historical controls.
  • 38% of the patients in treatment showed at least a 10-point improvement on the walking scale from baseline to week 28.
  • Also, 47% of NurOwn treated patients showed at least an 8-letter improvement across 28 weeks in a visual function test, and 67% showed at least a 3-point improvement on the cognitive processing scale.
  • NurOwn treated patients showed a mean improvement from baseline of 10% in 25-foot walk measure and a 4.8% improvement from baseline on the 9-9 hole peg test dominant hand, compared to 1.8% and 1.4% worsening respectively in matched historical controls.
  • Also, NurOwn treated patients showed a 6% improvement from baseline on the walking scale.
  • An increase in neuroprotective molecules and a decrease in neuroinflammatory biomarkers were observed.
  • Additional secondary efficacy data and detailed cerebrospinal fluid and blood biomarker analyses are currently underway and will be reported at upcoming scientific meetings.
  • Of the 20 patients enrolled, 18 were treated, and 16 completed the study. Two patients discontinued related to procedure-related adverse events. There were no study deaths or adverse events related to multiple sclerosis worsening.
  • Price Action: BCLI shares surge 21.9% at $4.78 in premarket trading on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAGeneralmultiple sclerosisPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!